Eos SENOLYTIX reports interim rat data for aging drug PTC‑2105 as Pulmatrix merger nears close
Eos SENOLYTIX disclosed early results from a 32‑week pre‑clinical study of its mitochondrial‑targeted peptide PTC‑2105 in aged rats, showing preserved motor function and a reduction in fat mass. The data come from the oldest cohort of 39 super‑aged rats, with a 0.5 mg/kg dose maintaining rotarod performance and a 12.5 mg/kg dose cutting fat mass by 14.5% versus 8.2% for control. The company plans to file an IND and start first‑in‑human trials in 2027, and its pending merger with Pulmatrix is slated to close in the fourth quarter of 2026. Pulmatrix shares fell 5.03% to $1.41 after the announcement.
Why it matters
The interim efficacy signals support advancing PTC‑2105 toward an IND filing, which could create a new therapeutic pipeline for sarcopenia and sarcopenic obesity. The pending merger, expected to close in Q4 2026, will combine the two companies and may affect Pulmatrix’s share price and liquidity.
Key facts
- 1The study runs for 32 weeks and includes 206 aged rats and 62 young rats. investing.com
- 2The oldest cohort consists of 39 rats that have reached the 16‑week assessment point. investing.com
- 3At week 16, rotarod latency with the 0.5 mg/kg dose stayed near baseline, while the vehicle group fell about 76 %. rttnews.com
- 4At week 8, fat mass fell 14.5 % from baseline with the 12.5 mg/kg dose, compared with an 8.2 % drop in the vehicle group. investing.com
- 5The merger with Pulmatrix is expected to be completed in the fourth quarter of 2026, pending standard closing conditions. investing.com
- 6Pulmatrix closed at $1.41 per share, down 5.03 % after the news. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.